| pubmed-article:11018857 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11018857 | lifeskim:mentions | umls-concept:C0019682 | lld:lifeskim |
| pubmed-article:11018857 | lifeskim:mentions | umls-concept:C0019699 | lld:lifeskim |
| pubmed-article:11018857 | lifeskim:mentions | umls-concept:C2349001 | lld:lifeskim |
| pubmed-article:11018857 | lifeskim:mentions | umls-concept:C0332307 | lld:lifeskim |
| pubmed-article:11018857 | lifeskim:mentions | umls-concept:C0681850 | lld:lifeskim |
| pubmed-article:11018857 | lifeskim:mentions | umls-concept:C1706203 | lld:lifeskim |
| pubmed-article:11018857 | lifeskim:mentions | umls-concept:C2697811 | lld:lifeskim |
| pubmed-article:11018857 | lifeskim:mentions | umls-concept:C0032105 | lld:lifeskim |
| pubmed-article:11018857 | lifeskim:mentions | umls-concept:C1749467 | lld:lifeskim |
| pubmed-article:11018857 | lifeskim:mentions | umls-concept:C0441889 | lld:lifeskim |
| pubmed-article:11018857 | lifeskim:mentions | umls-concept:C1539477 | lld:lifeskim |
| pubmed-article:11018857 | lifeskim:mentions | umls-concept:C1550501 | lld:lifeskim |
| pubmed-article:11018857 | lifeskim:mentions | umls-concept:C0887947 | lld:lifeskim |
| pubmed-article:11018857 | lifeskim:mentions | umls-concept:C1882115 | lld:lifeskim |
| pubmed-article:11018857 | pubmed:issue | 14 | lld:pubmed |
| pubmed-article:11018857 | pubmed:dateCreated | 2001-1-4 | lld:pubmed |
| pubmed-article:11018857 | pubmed:abstractText | Plasma levels of soluble Fas (sFas) are elevated in human immunodeficiency virus type 1 (HIV-1) infection, indicating dysregulation of the Fas apoptosis pathway and chronic immune activation. We performed a retrospective study to investigate the effects of HAART on plasma levels of sFas. A cross-sectional study of 27 drug-naive infected subjects and 49 patients under antiretroviral treatment showed that plasma levels of sFas were higher in HIV-1-infected subjects than in 52 HIV-1-negative controls, independently of the treatment status. In a longitudinal study of 69 patients undergoing HAART, we observed a minimal, but significant decrease in sFas plasma levels after 1 year of therapy. Levels of sFas, however, remained still higher than physiologic values. Patients undergoing HAART were further classified as nonresponders or responders on the basis of viremia suppression; no significant changes in plasma levels of sFas were observed between the two groups. These findings show that 1 year of HAART has a minor effect on the sFas levels in plasma. Long-term HAART may be required to normalize the dysregulation of the Fas apoptotic pathway and the persistent immune activation initiated by HIV-1. | lld:pubmed |
| pubmed-article:11018857 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11018857 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11018857 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11018857 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11018857 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11018857 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11018857 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11018857 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11018857 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:11018857 | pubmed:issn | 0889-2229 | lld:pubmed |
| pubmed-article:11018857 | pubmed:author | pubmed-author:AlbertJJ | lld:pubmed |
| pubmed-article:11018857 | pubmed:author | pubmed-author:SönnerborgAA | lld:pubmed |
| pubmed-article:11018857 | pubmed:author | pubmed-author:ZazziMM | lld:pubmed |
| pubmed-article:11018857 | pubmed:author | pubmed-author:ChiodiFF | lld:pubmed |
| pubmed-article:11018857 | pubmed:author | pubmed-author:De MilitoAA | lld:pubmed |
| pubmed-article:11018857 | pubmed:author | pubmed-author:HejdemanBB | lld:pubmed |
| pubmed-article:11018857 | pubmed:author | pubmed-author:AlemanSS | lld:pubmed |
| pubmed-article:11018857 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11018857 | pubmed:day | 20 | lld:pubmed |
| pubmed-article:11018857 | pubmed:volume | 16 | lld:pubmed |
| pubmed-article:11018857 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11018857 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11018857 | pubmed:pagination | 1379-84 | lld:pubmed |
| pubmed-article:11018857 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:11018857 | pubmed:meshHeading | pubmed-meshheading:11018857... | lld:pubmed |
| pubmed-article:11018857 | pubmed:meshHeading | pubmed-meshheading:11018857... | lld:pubmed |
| pubmed-article:11018857 | pubmed:meshHeading | pubmed-meshheading:11018857... | lld:pubmed |
| pubmed-article:11018857 | pubmed:meshHeading | pubmed-meshheading:11018857... | lld:pubmed |
| pubmed-article:11018857 | pubmed:meshHeading | pubmed-meshheading:11018857... | lld:pubmed |
| pubmed-article:11018857 | pubmed:meshHeading | pubmed-meshheading:11018857... | lld:pubmed |
| pubmed-article:11018857 | pubmed:meshHeading | pubmed-meshheading:11018857... | lld:pubmed |
| pubmed-article:11018857 | pubmed:meshHeading | pubmed-meshheading:11018857... | lld:pubmed |
| pubmed-article:11018857 | pubmed:meshHeading | pubmed-meshheading:11018857... | lld:pubmed |
| pubmed-article:11018857 | pubmed:meshHeading | pubmed-meshheading:11018857... | lld:pubmed |
| pubmed-article:11018857 | pubmed:meshHeading | pubmed-meshheading:11018857... | lld:pubmed |
| pubmed-article:11018857 | pubmed:meshHeading | pubmed-meshheading:11018857... | lld:pubmed |
| pubmed-article:11018857 | pubmed:meshHeading | pubmed-meshheading:11018857... | lld:pubmed |
| pubmed-article:11018857 | pubmed:meshHeading | pubmed-meshheading:11018857... | lld:pubmed |
| pubmed-article:11018857 | pubmed:meshHeading | pubmed-meshheading:11018857... | lld:pubmed |
| pubmed-article:11018857 | pubmed:meshHeading | pubmed-meshheading:11018857... | lld:pubmed |
| pubmed-article:11018857 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:11018857 | pubmed:articleTitle | High plasma levels of soluble fas in HIV type 1-infected subjects are not normalized during highly active antiretroviral therapy. | lld:pubmed |
| pubmed-article:11018857 | pubmed:affiliation | Microbiology and Tumor Biology Center, Karolinska Institutet, Stockholm, Sweden. | lld:pubmed |
| pubmed-article:11018857 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11018857 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11018857 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11018857 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11018857 | lld:pubmed |
